SPDR Dow Jones Industrial Average ETF

SPDR S&P 500 ETF Trust

Invesco QQQ Trust Series 1

GSI Technology, Inc. engages in the design, development and marketing of memory products primarily for the networking, and telecommunications markets. Its product includes Static Random Access Memory, or SRAM, which incorporated in networking and telecommunications equipment, such as routers, switches, wide area network infrastructure equipment, wireless base stations and network access equipment. It also offers services to the ongoing needs of the military, industrial, test and measurement equipment, automotive and medical markets for SRAMs .The company was founded by Lee-Lean Shu and Robert Yau in March 1995 and is headquartered in Sunnyvale, CA.

GSI Technology Inc

GSIT is trending due to a Cornell University study validating its Gemini-I APU's performance and energy efficiency compared to NVIDIA GPUs, sparking community excitement about its potential in AI and possible acquisition. Discussions also revolve around potential dilution from an ATM offering and the significance of the upcoming conference call. Some traders are noting potential short squeeze opportunities and comparing GSIT's technology to DeepSeek AI.

Replimune Group, Inc. is a clinical-stage biotechnology company. It engages in the business of developing oncolytic immunotherapies for the treatment of cancer. The company was founded by Philip Astley-Sparke, Colin A. Love, and Robert Coffin in March 2015 and is headquartered in Woburn, MA.

Replimune Group Inc

REPL is trending due to news of FDA acceptance of its Biologics License Application resubmission, sparking optimism and driving discussions around potential price targets. Community members are actively debating the company's future prospects, with some highlighting new price targets and potential breakouts, while others express skepticism and point to potential shorting opportunities. The stock's collaborations and setup are also being closely watched by traders.

Abercrombie & Fitch Co. engages in the retail of apparel, personal care products, and accessories. The firm operates through following geographical segments: Americas, EMEA and APAC. The Americas segment includes operations in North America and South America. The EMEA segment includes operations in Europe, the Middle East and Africa. The APAC segment includes operations in the Asia-Pacific region, including Asia and Oceania. The company was founded by David Abercrombie in 1892 and is headquartered in New Albany, OH.

Abercrombie & Fitch Co. - Ordinary Shares - Class A

Abercrombie & Fitch Co.

Abercrombie & Fitch is trending due to a recent sell-off, despite what some perceive as a strong underlying business and growth potential. Community members are actively debating whether the stock is oversold and a potential value play, with some pointing to a low forward P/E ratio and significant buyback authorization, while others cite concerns about tariffs and margin pressure.

CorMedix, Inc. is a pharmaceutical and medical device company, which engages in the development and commercialization of therapeutic products for the prevention and treatment of diseases and conditions. The company was founded by Antony E. Pfaffle on July 28, 2006 and is headquartered in Berkeley Heights, NJ.

CorMedix Inc

CRMD is trending due to recent financial results and future guidance, with community members discussing the company's potential for growth and profitability. Bullish investors point to institutional buying and the strategic investment in TLPH, while others are concerned about dilution and the company's acquisition strategy. The community is also closely watching for updates on partnerships and potential catalysts that could drive the stock higher.

Bitfarms Ltd. (Canada) engages in the business of mining cryptocurrency. The firm is also involved in the ownership and operation of server farms comprised of computers designed for the purpose of validating transactions on the Bitcoin blockchain. The company was founded by Emiliano Joel Grodzki and Nicolas Bonta in 2017 and is headquartered in Toronto, Canada.

Bitfarms Ltd.

Bitfarms (BITF) is trending as investors digest news of a $500M convertible note offering aimed at funding AI/HPC growth, sparking debates about potential dilution versus strategic expansion. The community is actively discussing CEO Ben Gagnon's upcoming space talk for further insights, with some viewing the recent dip as a buying opportunity amidst broader market volatility. Some investors believe Bitfarms is undervalued compared to its peers.

Verastem, Inc. is a biopharmaceutical company, which engages in the development and commercialization of drugs for the treatment of cancer. The company was founded by Richard H. Aldrich, Michelle Dipp, Piyush Gupta, Satish Jindal, Eric S. Lander, Robert F. Weinberg, and Christoph H. Westphal on August 4, 2010 and is headquartered in Needham, MA.

Verastem Inc

Verastem ($VSTM) is trending due to positive data from a partner's lung cancer drug trial in China, showing promising response rates and sparking optimism about its potential. The community is actively discussing the implications of these results, particularly in comparison to competitors and potential impact on future development. Some investors believe the positive news could trigger a short squeeze, while others remain cautious due to past volatility and management's history.

Cleveland-Cliffs, Inc. is a flat-rolled steel company, which engages in provision of iron ore pellets to the North American steel industry. It focuses on the production of metallic and coke, iron making, steelmaking, rolling and finishing, and downstream tubular components, stamping, and tooling. The company was founded in 1847 and is headquartered in Cleveland, OH.

Cleveland-Cliffs Inc

Cleveland-Cliffs is trending as the company explores rare earth mineral production, potentially transforming it into a strategic metals player amid tightening export controls from China. This pivot is sparking discussions about the company's growth potential beyond steel, with some seeing it as a smart move while others question execution and debt. Community members are closely monitoring its Q3 earnings report to determine if it can meet expectations.

Rigetti Computing, Inc. provides full-stack quantum computing services. It serves global enterprise, government, and research clients through its Rigetti Quantum Cloud Services platform. The company was founded by Chad Rigetti in 2013 and is headquartered in Berkeley, CA.

Rigetti Computing Inc

RGTI is trending downwards, with community chatter focusing on potential catalysts such as an upcoming offering and concerns about the company's financials. Some traders point to insider selling, including the CEO's past liquidation of shares, as a bearish signal, while others suggest the quantum computing sector still has room to run.

Robinhood Markets, Inc is a financial services platform, which engages in the provision of retail brokerage and offers trading in U.S. listed stocks and Exchange Traded Funds, related options, and cryptocurrency trading, as well as cash management, which includes debit cards services. The company was founded by Vladimir Tenev and Baiju Prafulkumar Bhatt in 2013 and is headquartered in Menlo Park, CA.

Robinhood Markets Inc - Ordinary Shares - Class A

Robinhood Markets Inc

Robinhood is trending amidst reports of widespread outages, reportedly linked to issues with Amazon Web Services (AWS), leaving users frustrated and unable to access the platform. The community is actively discussing the outage's impact on trading and potential market manipulation, while some see the stock's resilience as a bullish sign, anticipating a future earnings squeeze. Despite the technical difficulties, there's ongoing speculation about potential partnerships and future growth catalysts like prediction markets and banking services.

D-Wave Quantum, Inc. engages in the development and delivery of quantum computing systems, software, and services. It provides customers with access to the company’s quantum computing systems via the cloud in the form of quantum computing as a service. It offers professional services such as customer assistance in identifying and implementing quantum-computing applications. The company was founded on January 25, 2022 and is headquartered in Palo Alto, CA.

D-Wave Quantum Inc

D-Wave Quantum is trending amid community debate over its valuation and future prospects in the quantum computing sector. While some highlight customer case studies and potential for growth, others express concerns about revenue, cash burn, and insider selling. The stock's recent volatility and potential for further correction are also being actively discussed.

statis crypto Watchlist

Bitcoin

Ethereum

Solana

Ripple

Dogecoin

Cardano

statis IN Watchlist

Nifty 50

Nifty Bank

Reliance Industries Ltd.

Zomato Ltd.

Tata Consultancy Services

Tata Motors Ltd.

HDFC Bank Ltd.

ITC Ltd.

Adani Enterprises Ltd

Axis Bank Ltd

Bajaj Finance Ltd

statis US Watchlist

SPDR S&P 500 ETF

Apple Inc.

Tesla Inc

Microsoft Corporation

NVIDIA Corp

 Hey, I want to invite you to join Stocktwits. It’s the largest global community of active traders. You’ll get access to the real-time market insights, news, discussion and much more! You can sign up using my unique link below 
 


 has invited you to join Stocktwits

Are Investors Undervaluing Humana (HUM) Right Now?

Here at Zacks, our focus is on the proven Zacks Rank system, which emphasizes earnings estimates and estimate revisions to find great stocks. Nevertheless, we are always paying attention to the latest value, growth, and momentum trends to underscore strong picks.

Is Beam Therapeutics (BEAM) Stock Outpacing Its Medical Peers This Year?

Here is how Beam Therapeutics Inc. (BEAM) and Humana (HUM) have performed compared to their sector so far this year.

Humana (HUM) Forms 'Hammer Chart Pattern': Time for Bottom Fishing?

After losing some value lately, a hammer chart pattern has been formed for Humana (HUM), indicating that the stock has found support. This, combined with an upward trend in earnings estimate revisions, could lead to a trend reversal for the stock in the near term.

Humana (HUM) has reportedly lost a lawsuit seeking to undo cuts to the bonus payments it receives from the federal Medicare insurance program.Bloomberg <a class="st-link-external" target="_blank" rel="noopener noreferrer nofollow" href="https://www.bloomberg.com/news/articles/2025-10-14/humana-loses-second-lawsuit-to-reverse-medicare-bonus-cuts">reported</a> on Tuesday that a Texas judge ruled in favor of the federal government, affirming a downgrade of quality ratings that are tied to payments for Medicare Advantage. The judge had <a href="https://stocktwits.com/news-articles/markets/equity/humana-loses-lawsuit-over-medicare-bonus-cuts-stock-slides/ch8ks9QR5q8">dismissed</a> a similar case in July as well.Humana depends more than any other large insurer on revenue from the Medicare Advantage program, Bloomberg noted. About $3 billion was at stake in the lawsuit, the report said, citing consulting firm Capstone.Centers for Medicare &amp; Medicaid Services (CMS) assigns quality ratings, called stars, to Medicare Advantage plans, ranging from one to five, with five being the highest rating. Beneficiaries can use this data to help choose plans, and insurance companies can receive government bonus payments for higher ratings.Humana’s stock dropped as much as 4% at the time of writing. On Stocktwits, retail sentiment around <a href="https://stocktwits.com/symbol/HUM">HUM stock</a> stayed within the ‘bearish’ territory, coupled with ‘low’ message volume.<figure class="image"><img style="aspect-ratio:588/62;" src="https://news.stocktwits-cdn.com/Screenshot_2025_10_14_at_12_53_12_PM_png_e17a866cd8.webp" alt="HUM's Sentiment Meter and Message Volume as of 12:53 p.m. ET on Oct. 14, 2025 | Source: Stocktwits" width="588" height="62"><figcaption>HUM's Sentiment Meter and Message Volume as of 12:53 p.m. ET on Oct. 14, 2025 | Source: Stocktwits</figcaption></figure>Earlier this month, Humana <a href="https://stocktwits.com/news-articles/markets/equity/humana-stock-rises-after-insurer-reaffirms-full-year-earnings-guidance/chCrmVZR3fE">affirmed</a> its full-year earnings per share guidance provided in July.The insurer stated that it expects adjusted earnings per common share of $17 for the year ending Dec. 31, 2025, and diluted earnings per share of $13.77.The firm also stated that its preliminary 2026 Medicare Advantage (MA) Star Ratings align with the assumptions in its financial planning. As a result, there is no change to the incremental earnings potential for 2025 to 2028. The ratings data provided by the Centers for Medicare &amp; Medicaid Services was inadvertently accessible on CMS Plan Finder for a brief period on Oct. 1, 2025, the company stated.Humana has about 20% of its members currently enrolled in Medicare plans rated four stars and above for 2026, and 14% of members in 4.5-star plans for 2026, it said.“Based on all information available to date, the company remains confident in its 2026 Individual MA pricing and benefit design, including the expectation that it will double individual MA pre-tax margin in 2026 (excluding Stars), and believes it is positioned to return to membership growth in 2026,” the firm said.HUM stock rose 3% this year and fell about 2% over the past 12 months.&nbsp;Read also:&nbsp;<a href="https://stocktwits.com/news-articles/markets/equity/novavax-major-shareholder-calls-for-sale-of-company-to-larger-pharma-entity/ch6moRsR3mh">Novavax Major Shareholder Calls For Sale Of Company To Larger Pharma Entity</a>For updates and corrections, email newsroom[at]stocktwits[dot]com.

The MyHumana app page is displayed on a smartphone in the Apple App Store in front of the Humana Inc logo on October 30, 2024 in Chongqing, China. (Photo by Cheng Xin/Getty Images)

Humana Stock Slumps After Reportedly Losing Lawsuit Seeking To Undo Cuts To Medicare Bonus Payments

Bloomberg reported on Tuesday that a Texas judge ruled in favor of the federal government, affirming a downgrade of quality ratings that are tied to payments for Medicare Advantage.

Equity

Bloomberg reported on Tuesday that a Texas judge ruled in favor of the federal government, affirming a downgrade of quality ratings that are tied to payments for Medicare Advantage.


Humana Foundation Expands National Efforts to Improve Seniors Emotional Health

The Humana Foundation, the philanthropic arm of Humana Inc. (NYSE: HUM) for the past 44 years, today announced its ambition to become a national leader in addressing seniors emotional health. More...

CVS' Aetna Wins Big on 2026 MA Star Ratings: How to Play the Stock?

CVS' Aetna shines in 2026 Medicare Star Ratings, with more than 81% of members in four-star plans, fueling a 73.5% YTD stock surge and strong investor momentum.

Humana Inc. to Release Third Quarter 2025 Results on November 5, 2025

Humana Inc. (NYSE: HUM) will release its financial results for the third quarter 2025 (3Q25), as well as prepared management remarks (in PDF format), at 6:00 a.m. Eastern time on November 5, 2025...

Mizuho Securities raised price targets on several large U.S. health insurers following the release of the latest Medicare Advantage star ratings, noting improved visibility into earnings.Analyst Ann Hynes raised her target on CVS Health to $88 from $76, UnitedHealth to $430 from $300, Elevance Health to $420 from $342 and Humana to $345 from $300 and maintained an 'Outperform' rating on all four stocks. The firm also lifted Centene’s target to $40 from $28 with a 'Neutral' rating.Hynes said the target changes were driven by a broader rotation into the healthcare sector after the U.S. government released its 2026 quality ratings for Medicare Advantage and prescription drug plans, which help determine bonus payments to insurers.Barclays also raised its price targets in the group, lifting UnitedHealth’s to $386 from $352 and Elevance Health’s to $395 from $373, both with Overweight ratings. The firm said Medicare remains the most stable business line, Medicaid the most uncertain, and Affordable Care Act exchanges are improving both “fundamentally and from a policy perspective.”CVS Health’s Aetna unit led with over 81% of members in top-rated programs, followed by UnitedHealth at 78%, Elevance at 55%, and Humana at 20%, according to federal data and company disclosures.In all, 64% of Medicare Advantage members with drug coverage are signed up for plans that get four or five stars, Oppenheimer said. The Centers for Medicare &amp; Medicaid Services rates plans on metrics including patient satisfaction, and performance on cancer screenings and management of chronic conditions, among others, according to a Reuters&nbsp;<a class="st-link-external" target="_blank" rel="noopener noreferrer nofollow" href="https://www.reuters.com/legal/litigation/cvs-says-over-81-members-are-high-rated-medicare-advantage-plans-2026-2025-10-09/">report</a>.Four and five-star plans receive bigger government payments that could add up to billions of dollars and have a financial impact in 2027, Oppenheimer said. The research firm added that results broadly matched expectations following company pre-announcements.&nbsp;Elevance showed one of the largest year-over-year gains, with 55% of its membership now in plans rated four stars or higher, up from 40% a year ago, while CVS said 63% of Aetna members are in 4.5-star plans. UnitedHealth said 40% of its members are in 4.5-star plans, and Humana reported 1.2 million members in highly rated offerings.Centene’s Wellcare CEO Michael Carson said the company was encouraged by progress in its star ratings.On Stocktwits, retail sentiment was ‘bullish’ for CVS Health amid ‘normal’ message volume, while sentiment for UnitedHealth, Elevance Health, Humana, and Centene was ‘bearish’ with ‘low’ message volume.So far this year, CVS Health shares are up 77%, while Humana has gained 16%. In contrast, UnitedHealth is down 26%, Elevance Health has slipped 2%, and Centene has dropped 38%.For updates and corrections, email newsroom[at]stocktwits[dot]com.

In this photo illustration, the United States Medicare logo is seen displayed on a smartphone screen. (Photo Illustration by Thomas Fuller/SOPA Images/LightRocket via Getty Images)

CVS, UnitedHealth, Elevance, Humana Gain Price Target Hikes On Wall Street After Medicare Star Ratings Update

Barclays raised targets on UnitedHealth and Elevance, saying Medicare remains the most stable business line, Medicaid the most uncertain, and Affordable Care Act exchanges are improving both fundamentally and from a policy standpoint.

Can Digital Workflows at Optum Rx Transform UNH's Patient Experience?

UnitedHealth drives a digital overhaul at Optum Rx, automating pharmacy workflows to boost efficiency and enrich patient care.

CVS Health's Aetna Advances Initiative to Curb Hospital Readmissions

CVS company, Aetna, expands its Aetna Clinical Collaboration program to 10 hospitals, aiming to cut readmissions and ease hospital workloads.

Humana Inc. engages in the provision of health insurance services. It operates through the Insurance and CenterWell segments. The Insurance segment consists of Medicare benefits, marketed to individuals or directly via group Medicare accounts, as well as contract with CMS to administer the Limited Income Newly Eligible Transition, or LI-NET, prescription drug plan program and contracts with various states to provide Medicaid, dual eligible demonstration, and Long-Term Support Services benefits, which refer to as state-based contracts. The CenterWell segment represents payor-agnostic healthcare services offerings, including pharmacy dispensing services, provider services, and home services. The company was founded by David A. Jones, Sr., and Wendell Cherry on August 18, 1961 and is headquartered in Louisville, KY.

Humana Inc.

Will Netflix ($NFLX) beat quarterly earnings? 
 
*Powered by Polymarket

Stocktwits

Netflix Inc

) beat quarterly earnings? 
 
*Powered by Polymarket

HUM
Humana Inc

Feed

News

Sentiment

Earnings

Fundamentals

Info

Poll

Latest HUM News

HUMHumana Inc